Novel imatinib amide derivatives (a1-28, b1-9) were synthesized and evaluated for their biological activities.
All compounds were characterized by 1H NMR, MS and elemental analysis. Among all the derivatives, compounds a4,
a10, a21, b1 and b2 displayed the most significant ability of inhibiting K562 cell proliferation with the IC50 values of
0.67, 0.66, 0.65, 0.59 and 0.62 µM, respectively, indicating that these compounds were potent inhibitors of Bcr-Abl in
leukemic K562 cells, comparable to the reference compound imatinib. Molecular docking study was performed to position
compounds a21 and b1 into the active site of Abl to determine the probable binding modes.
新型的
伊马替尼酰胺衍
生物(a1-28, b1-9)被合成并评估了它们的
生物活性。所有化合物均通过1H NMR、质谱及元素分析进行了表征。在所有衍
生物中,化合物a4、a10、a21、b1和b2显示出最强的抑制K562细胞增殖能力,其IC50值分别为0.67、0.66、0.65、0.59和0.62 µM,表明这些化合物是白血病K562细胞中Bcr-Abl的有效
抑制剂,与参考化合物
伊马替尼相当。分子对接研究用于将化合物a21和b1定位到Abl的活性位点,以确定可能的结合模式。